Falsified Medicines Directive 2011/62/EU Released

Falsified Medicines Directive

By the deadline of 9th February 2019, all manufacturers supplying pharmaceutical products to European countries will have to comply with the requirements set out in the Falsified Medicines Directive 2011/62/EU. 

The Falsified Medicines Directive refers to particular safety features, how medicine authenticity should be verified, and by whom all form part of the Directive which was adopted on 2nd October 2015 and published, after scrutiny by the European Parliament and the Council, on 9th February 2016. Pharmaceutical manufacturers and Contract Manufacturing Organisations (CMOs) that need to comply with the FMD should start now if their sites will be compliant for the deadline in 2019. 

Our dedicated teams work with our clients to secure your supply chain. Our products help eliminate dangerous counterfeit, or substandard products from your supply chain. After 20 years in the life science and pharma industry, we understand our clients needs. We understand that packaging plays a crucial role in preventing the trade of counterfeit pharmaceutical products and medical devices. Our ongoing research, development and innovation means that our products are built to exceptional standards. Please feel free to contact us to discuss your needs. 

In the meantime, you can read the detailed rules and requirements for compliance, which were published in February 2016, here: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2016_161/reg_2016_161_en.pdf

Read the Directive in full here: http://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2011_62/dir_2011_62_en.pdf

 

Share This